Adipose tissue, insulin resistance and low-grade inflammation: Implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy

Climacteric

Volumn 9, Issue 3, 2006, Pages 169-180

  Tanko L B ^a   Christiansen, C ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Adiponectin; Body fat distribution; Cardiovascular risks; Hormone therapy; Obesity; Postmenopausal women

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; ESTRADIOL; ESTROGEN; GESTAGEN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY FAT; CARDIOVASCULAR RISK; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; MEDLINE; OBESITY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ADIPONECTIN; ADIPOSE TISSUE; ARTERIOSCLEROSIS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PROGESTINS; RISK FACTORS;

EID: 33646696401     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130600738765     Document Type: Review

References (54)

1. Wenger NK. Coronary heart disease: the female heart is vulnerable. Prog Cardiovasc Dis 2003;46:199-229
2. Ferrannini E, Balkau B. Insulin: in search of a syndrome. Diabet Med 2002;19:724-9
3. McGill HC Jr, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-18
4. Miyazaki M, Babazono A, Ishii T, et al. Effects of low body mass index and smoking on all-cause mortality among middle-aged and elderly Japanese. J Epidemiol 2002;12:40-4
5. Vandenbroucke JP, Mauritz BJ, de Bruin A, et al. Weight, smoking, and mortality. JAMA 1984;252:59-60
6. Tankó LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation 2003;107:1626-31
7. Tatsukawa M, Kurokawa M, Tamari Y, Yoshimatsu H, Sakata T. Regional fat deposition in the legs is useful as a presumptive marker of antiatherogenecity in Japanese. Proc Soc Exp Biol Med 2000;223:156-62
8. Sjostrom CD, Hakangard AC, Lissner L, Sjostrom L. Body compartment and subcutaneous adipose tissue distribution - risk factor patterns in obese subjects. Obes Res 1995;3:9-22
9. Seidell JC, Perusse L, Despres J-P, Bouchard C. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 2001;74:315-21
10. Tankó LB, Bagger YZ, Alexandersen P, Christiansen C, Larsen PJ. Peripheral adiposity and cardiovascular risk. Circulation 2003;108:e164
11. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM. Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am J Physiol Endocrinol Metab 2002;282:E1023-8
12. Tankó LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in elderly women. Eur Heart J 2003;24:1531-7
13. Snijder MB, Dekker JM, Visser M, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr 2003;77:1192-7
14. Okura T, Nakata Y, Yamabuki K, Tanaka K. Regional body composition changes exhibit opposing effects of coronary heart disease risk factors. Arterioscler Thromb Vasc Biol 2004;24:923-9
15. Tankó LB, Bruun JM, Alexandersen P, et al. Novel association between bioavailable estradiol and adipokines in postmenopausal women with different phenotypes of obesity: implications for atherogenesis. Circulation 2004;110:2246-52
16. Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001;103:1529-34
17. Lissner L, Bjorkelund C, Heitmann BL, Seidell JC, Bengtsson C. Larger hip circumference independently predicts health and longevity in a Swedish female cohort. Obes Res 2001;9:644-6
18. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56
19. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808
20. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005;90:2282-9
21. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:7265-70
22. Takahashi K, Mizuarai S, Araki H, et al. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J Biol Chem 2003;278:46654-60
23. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997;82:4196-200
24. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996;45:881-5
25. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001;280:E745-51
26. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001;60:349-56
27. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005;5:70-5
28. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50
29. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34
30. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002;288:980-7
31. Fisher FM, McTernan PG, Valsamakis G, et al. Differences in adiponectin expression: effect of fat depots and type 2 diabetes status. Horm Metab Res 2002;34:650-4
32. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003;148:293-300
33. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004;24:29-33
34. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-6
35. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-4
36. Okamoto Y, Kihara S, Ouchi N, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767-70
37. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005;111:747-53
38. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7
39. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005;5:323-32
40. Kirschner MA, Samojlik E. Sex hormone metabolism in upper and lower body obesity. Int J Obes 1991;15:101-8
41. Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of IR in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:3626-31
42. Tankó LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Can glucocorticoid homeostasis explain the antiatherogenic effect of peripheral adiposity? Circulation 2003;108:e61
43. Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause 2005;12:308-17
44. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV; Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995-1998. Circulation 2003;107:43-8
45. Lokkegaard E, Pedersen AT, Heitmann BL, et al. Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. BMJ 2003;326:426
46. Howard BV, Hsia J, Ouyang P, et al. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110:201-6
47. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
48. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: a prospective, observational study. Ann Intern Med 2001;135:1-8
49. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
50. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
51. Sites CK, L'hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2005;90:2701-7
52. Tankó LB, Christiansen C. Effects of estradiol plus different doses of drospirenone on body fat mass, adiponectin and atherogenic risk factors in postmenopausal women. J Intern Med 2005;258(6):544-53
53. Im JA, Lee JW, Lee HR, Lee DC. Plasma adiponectin levels in postmenopausal women with or without long-term hormone therapy. Maturitas 2006;54:65-71
54. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33